• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

PRODUCT FILTERS

REGION

1,094
79
60
57
47

COUNTRY

55
17
8
6
5

CATEGORIES

  • 82
  • 121
  • 66
  • 66
  • 36
  • 37
  • 12
  • 11
  • 12
  • 18

PRICE

546
811
1,671
2,601

PUBLISHED

195
291
747
2,601

PRODUCT TYPE

2,454
72
62
12
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE
p53 Signaling Pathway in Cancer Drug Pipeline Update 2015 p53 Signaling Pathway in Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

p53 Signaling Pathway in Cancer Drug Pipeline Update 2015

p53 activation is induced by a number of stress signals, including DNA damage, oxidative stress and activated oncogenes. The p53 protein is employed as a transcriptional activator of p53-regulated genes....

January 2015
FROM
ErbB Signaling Pathway in Cancer Drug Pipeline Update 2015 ErbB Signaling Pathway in Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

ErbB Signaling Pathway in Cancer Drug Pipeline Update 2015

The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation,...

January 2015
FROM
Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update 2015 Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

Targeting Focal Adhesion for the Treatment of Cancer Drug Pipeline Update 2015

Cell-matrix adhesions play essential roles in important biological processes including cell motility, cell proliferation, cell differentiation, regulation of gene expression and cell survival. At the...

January 2015
FROM
Targeting Cell Adhesion Molecules (CAMs) for the Treatment of Cancer Drug Pipeline Update 2015 Targeting Cell Adhesion Molecules (CAMs) for the Treatment of Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

Targeting Cell Adhesion Molecules (CAMs) for the Treatment of Cancer Drug Pipeline Update 2015

Cell adhesion molecules are (glyco)proteins expressed on the cell surface and play a critical role in a wide array of biologic processes that include hemostasis, the immune response, inflammation, embryogenesis,...

January 2015
FROM
Targeting Tight Junctions in Cancer Drug Pipeline Update 2015 Targeting Tight Junctions in Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

Targeting Tight Junctions in Cancer Drug Pipeline Update 2015

Epithelial tight junctions (TJs) are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many...

January 2015
FROM
Targeting Metabolic Pathways in Cancer Drug Pipeline Update 2015 Targeting Metabolic Pathways in Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

Targeting Metabolic Pathways in Cancer Drug Pipeline Update 2015

There are today 173 companies plus partners developing 171 metabolic pathways targeting drugs in 478 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number...

January 2015
FROM
Modulators of the Actin Cytoskeleton for the Treatment of Cancer Drug Pipeline Update 2015 Modulators of the Actin Cytoskeleton for the Treatment of Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

Modulators of the Actin Cytoskeleton for the Treatment of Cancer Drug Pipeline Update 2015

There are today 196 companies plus partners developing 282 targeting actin cytoskeleton modulators drugs in 1242 developmental projects in cancer. In addition, there is 1 suspended drug and the accumulated...

January 2015
FROM
Orphan Drugs in Oncology Drug Pipeline Update 2015 Orphan Drugs in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

Orphan Drugs in Oncology Drug Pipeline Update 2015

This is a worldwide report on cancer drugs which have now or in the past received orphan drug status. This product will give you unique access not only to those cancer indications in which drugs are...

January 2015
FROM
Transcriptional Misregulation in Cancer Drug Pipeline Update 2015 Transcriptional Misregulation in Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

Transcriptional Misregulation in Cancer Drug Pipeline Update 2015

There are today 238 companies plus partners developing 279 transcriptional misregulation targeting drugs in 1203 developmental projects in cancer. In addition, there are 4 suspended drugs and the accumulated...

January 2015
FROM
HIF-1 Signaling Pathway in Cancer Drug Pipeline Update 2015 HIF-1 Signaling Pathway in Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

HIF-1 Signaling Pathway in Cancer Drug Pipeline Update 2015

Cancer cells are characterized by rapid proliferation and require adaptive metabolic responses to allow continued biosynthesis and cell growth in the setting of decreased oxygen (O(2)) and nutrient...

January 2015
FROM
NOD-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2015 NOD-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

NOD-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2015

Specific families of pattern recognition receptors are responsible for detecting various pathogens and generating innate immune responses. The intracellular NOD-like receptor (NLR) family contains more...

January 2015
FROM
Viral Carcinogenesis Drug Pipeline Update 2015 Viral Carcinogenesis Drug Pipeline Update 2015 - Product Thumbnail Image

Viral Carcinogenesis Drug Pipeline Update 2015

There is a strong association between viruses and the development of human malignancies. We now know that at least six human viruses, Epstein-Barr virus (EBV), hepatitis B virus (HBV), hepatitis C virus...

January 2015
FROM
Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2015 Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

Toll-Like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2015

Specific families of pattern recognition receptors are responsible for detecting microbial pathogens and generating innate immune responses. Toll-like receptors (TLRs) are membrane-bound receptors identified...

January 2015
FROM
RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2015 RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update 2015

Potentially any disease-causing gene, cell type or tissue can be targeted with miRNA, RNAi or siRNA, including those not ’druggable’ with small molecules or protein-based therapies. There are today...

January 2015
FROM
PI3K-Akt Signaling Pathway in Cancer Drug Pipeline Update 2015 PI3K-Akt Signaling Pathway in Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

PI3K-Akt Signaling Pathway in Cancer Drug Pipeline Update 2015

The phosphatidylinositol 3' -kinase(PI3K)-Akt signaling pathway is activated by many types of cellular stimuli or toxic insults and regulates fundamental cellular functions such as transcription, translation,...

January 2015
FROM
The MAPK Signaling Pathway in Oncology Drug Pipeline Update 2015 The MAPK Signaling Pathway in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

The MAPK Signaling Pathway in Oncology Drug Pipeline Update 2015

The mitogen-activated protein kinase (MAPK) cascade is a highly conserved module that is involved in various cellular functions, including cell proliferation, differentiation and migration. There are...

January 2015
FROM
RIG-I-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2015 RIG-I-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

RIG-I-like Receptor Signaling Pathway in Cancer Drug Pipeline Update 2015

Specific families of pattern recognition receptors are responsible for detecting viral pathogens and generating innate immune responses. Non-self RNA appearing in a cell as a result of intracellular...

January 2015
FROM
Notch Signaling Pathway in Oncology Drug Pipeline Update 2015 Notch Signaling Pathway in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

Notch Signaling Pathway in Oncology Drug Pipeline Update 2015

Aberrant Notch signaling has been linked to a number of malignancies including leukemias, lymphomas and carcinomas of the breast, skin, lung, cervix and kidneys. There are today 266 companies plus...

January 2015
FROM
Cell Cycle Targeting in Cancer Drug Pipeline Update 2015 Cell Cycle Targeting in Cancer Drug Pipeline Update 2015 - Product Thumbnail Image

Cell Cycle Targeting in Cancer Drug Pipeline Update 2015

There are today 147 companies plus partners developing 144 targeting the cell cycle drugs in 586 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number...

January 2015
FROM
Fc Epsilon RI Signaling Pathway in Oncology Drug Pipeline Update 2015 Fc Epsilon RI Signaling Pathway in Oncology Drug Pipeline Update 2015 - Product Thumbnail Image

Fc Epsilon RI Signaling Pathway in Oncology Drug Pipeline Update 2015

Fc epsilon RI-mediated signaling pathways in mast cells are initiated by the interaction of antigen (Ag) with IgE bound to the extracellular domain of the alpha chain of Fc epsilon RI. The activation...

January 2015
FROM
Loading Indicator

Our Clients

Photocure ASA Roche Diagnostics Ltd. Abbott Laboratories Ltd. Pfizer, Inc. Novartis AG Becton, Dickinson and Company (BD)